The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Which patients with NSCLC will potentially benefit from cemiplimab?
Ana Baramidze, MD, PhD, Todua Clinic, Tbilisi, Georgia, highlights the benefits of cemiplimab treatment in patients with lung cancer, noting that patients regardless of PD-L1 expression levels can experience benefits from cemiplimab treatment. Studies have indicated that a significant proportion of patients, who have completed cemiplimab plus chemotherapy, had favorable overall survival and other endpoints compared to chemotherapy alone. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So patients regardless of PD-L1 expression levels have benefits with the treatment of cemiplimab and also it’s important to note that a big amount of the patients have completed the treatment with cemiplimab plus chemotherapy and the overall survival and all other endpoints were very favorable cemiplimab plus chemotherapy versus chemotherapy
This transcript is AI-generated...
So patients regardless of PD-L1 expression levels have benefits with the treatment of cemiplimab and also it’s important to note that a big amount of the patients have completed the treatment with cemiplimab plus chemotherapy and the overall survival and all other endpoints were very favorable cemiplimab plus chemotherapy versus chemotherapy
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
